DR. CLIFTON SCOTT NICHOLSON-UHL M.D
Prescription History 1184706913
Specialist in Marrero, LA


Quality Rating: 96.9 out of 100 score

NPI Status: Active since October 20, 2006

Contact Information

1111 MEDICAL CENTER BLVD
SUITE 250S
MARRERO, LA
ZIP 70072
Phone: (504) 349-6945
Fax: (504) 349-6949

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. CLIFTON SCOTT NICHOLSON-UHL M.D, an active Specialist specialist practicing in Marrero, LA. Our medical registry currently tracks 12 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 326 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 87 claims alone.


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 17
30-Day Fills 47.6
Days Supply 1,428
LA State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills99.2
Peer Average Days Supply2,927
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.3% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $43.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$2.54

State Avg Cost Per Claim

$9.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Escitalopram Oxalate

Generic Formulation: Escitalopram OxalateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 12
30-Day Fills 36.0
Days Supply 1,080
LA State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills114.2
Peer Average Days Supply3,357
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.0% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $157.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.12

State Avg Cost Per Claim

$12.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.

Therapeutic Applications

Escitalopram is used to treat depression and anxiety. It works by helping to restore the balance of a certain natural substance (serotonin) in the brain. Escitalopram belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRI). It may improve your energy level and feelings of well-being and decrease nervousness.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 87
30-Day Fills 167.0
Days Supply 4,973
LA State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills91.4
Peer Average Days Supply2,724
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 102.3% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,788.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$55.04

State Avg Cost Per Claim

$45.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Linzess

Generic Formulation: LinaclotideSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 27
30-Day Fills 65.0
Days Supply 1,950
LA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills54.7
Peer Average Days Supply1,600
Conservative Utilization

This provider writes prescriptions for this formulation 32.5% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $35,610.87 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,318.92

State Avg Cost Per Claim

$692.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

See also Warning section. Linaclotide is used to treat certain types of bowel problems (irritable bowel syndrome with constipation, chronic idiopathic constipation). It works by increasing fluid in your intestines and helping speed up movement of food through the gut. Linaclotide may improve stool texture and lessen symptoms such as bloating, abdominal pain/discomfort, straining, and feelings of incomplete bowel movements.

Metronidazole

Generic Formulation: MetronidazoleSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 89
LA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.0
Peer Average Days Supply309
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $633.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.23

State Avg Cost Per Claim

$40.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.

Therapeutic Applications

This medication is used on the skin to treat a certain skin disorder known as rosacea, a type of adult acne. It may help to decrease redness, swelling and the number of pimples caused by rosacea. This medication is an antibiotic. For the treatment of rosacea, metronidazole is believed to work by decreasing swelling (inflammation). Some brands of this medication also contain sunscreens (see also Notes section).

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 11
30-Day Fills 25.0
Days Supply 750
LA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills74.2
Peer Average Days Supply2,190
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.8% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $58.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.34

State Avg Cost Per Claim

$37.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 31
30-Day Fills 46.0
Days Supply 1,380
LA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills33.1
Peer Average Days Supply977
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 47.6% more claims than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,013.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$290.77

State Avg Cost Per Claim

$344.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Prolia

Generic Formulation: DenosumabSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 12
30-Day Fills 72.0
Days Supply 2,160
LA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills160.7
Peer Average Days Supply4,813
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,108.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,592.35

State Avg Cost Per Claim

$1,563.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A humanized monoclonal antibody and an inhibitor of the RANK LIGAND, which regulates OSTEOCLAST differentiation and bone remodeling. It is used as a BONE DENSITY CONSERVATION AGENT in the treatment of OSTEOPOROSIS.

Therapeutic Applications

Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone.

Raloxifene Hcl

Generic Formulation: Raloxifene HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 48
30-Day Fills 106.0
Days Supply 3,160
LA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills42.4
Peer Average Days Supply1,264
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 118.2% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,521.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$52.52

State Avg Cost Per Claim

$67.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Therapeutic Applications

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

Valacyclovir

Generic Formulation: Valacyclovir HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 34
30-Day Fills 38.3
Days Supply 955
LA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills30.4
Peer Average Days Supply661
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 54.5% higher than the standard regional baseline profile for LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $570.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.78

State Avg Cost Per Claim

$42.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.

Therapeutic Applications

Valacyclovir is used to treat infections caused by certain types of viruses. In children, it is used to treat cold sores around the mouth (caused by herpes simplex) and chickenpox (caused by varicella zoster). In adults, it is used to treat shingles (caused by herpes zoster) and cold sores around the mouth. Valacyclovir is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, this medication is used to reduce the number of future episodes. Valacyclovir is an antiviral drug. It stops the growth of certain viruses. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Valacyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal.

Venlafaxine Hcl Er

Generic Formulation: Venlafaxine HclSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 12
30-Day Fills 36.0
Days Supply 1,080
LA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills69.6
Peer Average Days Supply2,044
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.7% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $69.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.80

State Avg Cost Per Claim

$21.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Venlafaxine is used to treat depression, anxiety, panic attacks, and social anxiety disorder (social phobia). It may improve your mood and energy level and may help restore your interest in daily living. It may also decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. Venlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Yuvafem

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 570
LA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills26.1
Peer Average Days Supply760
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,354.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$67.74

State Avg Cost Per Claim

$127.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. CLIFTON SCOTT NICHOLSON-UHL M.D provides transparency into local medical care patterns within Marrero, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.